BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28165251)

  • 1. Enantioselective Synthesis of 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) via Enzymatic Desymmetrization.
    McLaughlin M; Kong J; Belyk KM; Chen B; Gibson AW; Keen SP; Lieberman DR; Milczek EM; Moore JC; Murray D; Peng F; Qi J; Reamer RA; Song ZJ; Tan L; Wang L; Williams MJ
    Org Lett; 2017 Feb; 19(4):926-929. PubMed ID: 28165251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concise synthesis of the anti-HIV nucleoside EFdA.
    Kageyama M; Miyagi T; Yoshida M; Nagasawa T; Ohrui H; Kuwahara S
    Biosci Biotechnol Biochem; 2012; 76(6):1219-25. PubMed ID: 22790950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective total synthesis of the potent anti-HIV nucleoside EFdA.
    Kageyama M; Nagasawa T; Yoshida M; Ohrui H; Kuwahara S
    Org Lett; 2011 Oct; 13(19):5264-6. PubMed ID: 21888325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.
    Muftuoglu Y; Sohl CD; Mislak AC; Mitsuya H; Sarafianos SG; Anderson KS
    Antiviral Res; 2014 Jun; 106():1-4. PubMed ID: 24632447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nine-Step Stereoselective Synthesis of Islatravir from Deoxyribose.
    Nawrat CC; Whittaker AM; Huffman MA; McLaughlin M; Cohen RD; Andreani T; Ding B; Li H; Weisel M; Tschaen DM
    Org Lett; 2020 Mar; 22(6):2167-2172. PubMed ID: 32108487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of EFdA via a diastereoselective aldol reaction of a protected 3-keto furanose.
    Fukuyama K; Ohrui H; Kuwahara S
    Org Lett; 2015 Feb; 17(4):828-31. PubMed ID: 25642994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).
    Salie ZL; Kirby KA; Michailidis E; Marchand B; Singh K; Rohan LC; Kodama EN; Mitsuya H; Parniak MA; Sarafianos SG
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9274-9. PubMed ID: 27489345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
    Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
    Maeda K; Desai DV; Aoki M; Nakata H; Kodama EN; Mitsuya H
    Antivir Ther; 2014; 19(2):179-89. PubMed ID: 24162098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
    Wu VH; Smith RA; Masoum S; Raugi DN; Ba S; Seydi M; Grobler JA; Gottlieb GS;
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
    Hattori S; Ide K; Nakata H; Harada H; Suzu S; Ashida N; Kohgo S; Hayakawa H; Mitsuya H; Okada S
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3887-93. PubMed ID: 19546363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric synthesis of cyclobutanones: synthesis of cyclobut-G.
    Darses B; Greene AE; Poisson JF
    J Org Chem; 2012 Feb; 77(4):1710-21. PubMed ID: 22283963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention.
    Zhang W; Parniak MA; Mitsuya H; Sarafianos SG; Graebing PW; Rohan LC
    Drug Dev Ind Pharm; 2014 Aug; 40(8):1101-11. PubMed ID: 23841536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.
    Sohl CD; Singh K; Kasiviswanathan R; Copeland WC; Mitsuya H; Sarafianos SG; Anderson KS
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1630-4. PubMed ID: 22155823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General scope of 1,4-diastereoselective additions to a 2(3H)-quinazolinone: practical preparation of HIV therapeutics.
    Magnus NA; Confalone PN; Storace L; Patel M; Wood CC; Davis WP; Parsons RL
    J Org Chem; 2003 Feb; 68(3):754-61. PubMed ID: 12558396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.
    Shi J; McAtee JJ; Schlueter Wirtz S; Tharnish P; Juodawlkis A; Liotta DC; Schinazi RF
    J Med Chem; 1999 Mar; 42(5):859-67. PubMed ID: 10072683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective synthesis of beta-L-2',3'-dideoxy- and L-2',3'-didehydro-2',3'-dideoxy purine nucleosides.
    Wang P; Bolon PJ; Newton MG; Chua CK
    Nucleosides Nucleotides; 1999; 18(11-12):2819-35. PubMed ID: 10639757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers.
    Zhang W; Parniak MA; Sarafianos SG; Empey PE; Rohan LC
    Eur J Pharmacol; 2014 Jun; 732():86-95. PubMed ID: 24690257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The triphosphate of beta-D-4'-C-ethynyl-2',3'-dideoxycytidine is the preferred enantiomer substrate for HIV reverse transcriptase.
    Siddiqui MA; Marquez VE
    Bioorg Med Chem; 2007 Jan; 15(1):283-7. PubMed ID: 17046266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A concise and selective synthesis of novel 5-aryloxyimidazole NNRTIs.
    Jones LH; Dupont T; Mowbray CE; Newman SD
    Org Lett; 2006 Apr; 8(8):1725-7. PubMed ID: 16597151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.